ZyGEM Corp. Ltd., announced several developments supporting the advancement of its integrated microfluidics platform designed to dramatically decrease the time, complexity and cost of conducting DNA testing.
InhibOx Ltd announces LOx 2.0 - a flexible system to identify and optimize drug lead candidates through preserving and linking critical features with new scaffolds.
Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.
Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants — including those with the apparent ability to prevent cancer — may actually aggravate or even cause cancer in some individuals.
GlobeImmune Inc. announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment of hepatitis C virus infection. The company previously reported a 60% improvement in sustained virologic response.
LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing vaccine products, announced positive results from a Phase 1/2 challenge study of its norovirus virus-like particle (VLP) vaccine candidate.
Regulus Therapeutics Inc. announced that they have received a $10 million equity investment from sanofi-aventis. The investment makes sanofi-aventis the third investor in Regulus, along with its founding companies Alnylam and Isis.
Michigan Attorney General Mike Cox says the state will get a $4.7 million share of a $750 million settlement of claims that GlaxoSmithKline distributed adulterated drugs.
Teens should get a booster dose of the vaccine for bacterial meningitis because a single shot doesn't work as long as expected, a federal advisory panel said.
A night light that scares away mosquitoes possibly carrying malaria is among nine ideas the Bill & Melinda Gates Foundation thinks are worth more research dollars, after giving more than 300 scientists seed money to take an initial look at some far-out notions.
Affymetrix, Inc., reported its operating results for the third quarter of 2010. Total revenue for the quarter was $74.0 million as compared to total revenue of $78.2 million in the third quarter of 2009.
Irish drugmaker Elan Corp. reported a third-quarter net loss as it paid down debts, cut research and development costs, and focused on increasing sales of drugs that combat multiple sclerosis.
French pharmaceutical company Sanofi-Aventis SA said its net profit rose 13 percent in the third quarter thanks to strong demand in emerging markets and acquisitions in the consumer health care field.
Pharmaceutical company AstraZeneca on Thursday reported a 27 percent drop in third-quarter profit as it set aside nearly half a billion dollars to settle claims that its anti-psychotic drug Seroquel has harmful side-effects.
Bayer AG's third-quarter earnings rose 12 percent as sales of farm products and high-tech materials boosted revenue at the pharmaceutical and chemical company, helping balance out slower growth at its drug division.